Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Moderate to Severe Plaque Psoriasis
NCT01265823Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2010
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in plaque psoriasis, sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at 16 weeks and Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at 16 weeks. Started Oct 2010; status: completed.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01265823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265823.